Anne M. Phillips - 10 Jun 2025 Form 4 Insider Report for Barinthus Biotherapeutics plc. (BRNS)

Reporting relationship: Director
Issuer ticker: BRNS
Reported as of: 10 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2025, 17:15:31 UTC
Prior SEC filing: 10 Jun 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ William Enright, Attorney-in-Fact

Key filing fact

Anne M. Phillips filed Form 4 for Barinthus Biotherapeutics plc. (BRNS) on 11 Jun 2025.

Key facts

This page summarizes Anne M. Phillips's Form 4 filing for Barinthus Biotherapeutics plc. (BRNS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2025, 17:15.

Change

Previous filing in this sequence was filed on 10 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001627680 Primary reporting owner

Phillips Anne M.

Relationship: Director
Address: UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT, UNITED KINGDOM
Signature: /s/ William Enright, Attorney-in-Fact
Signature date: 11 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BRNS transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,174
Change %
Price: $0.000000
Shares after: 20,174
Date: 10 Jun 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 20,174
Exercise price: $1.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Footnote F2

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.